Biologics

01Overview and value chain#

Markers EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Biologics are drugs produced by living systems: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fragment and bispecific antibodies, and advanced ATMPs (CAR-T, gene therapy). It is the largest drug class: a $400B+ global market, and biologics are >60% of big-pharma pipelines. mAb production in CHO cell lines reaches 2–10 g/L titers in fed-batch, and the platform (cell line → bioreactor → purification) is reproducible across molecules. ADCs and CAR-T extend the platform into targeted oncology.

Key directions of biologics:

1. Monoclonal antibodies (Monoclonal Antibodies): blockers (Humira, Keytruda), bispecifics.
2. Antibody-drug conjugates (Antibody-Drug Conjugates): Enhertu; the Pfizer–Seagen $43B deal.
3. CAR-T and cell therapy (CAR-T & Cell Therapy): Kymriah, Yescarta; ~$400k per course.
4. Gene therapy (Gene Therapy): Zolgensma, Luxturna — single-dose treatment of inherited disease.

Sectoral value chain#

[cell line] ──> [upstream] ──> [purification] ──> [formulation]
                    │
              (CHO, 2–10 g/L titer)
                    │
                    ▼
[drug product] <─── [fill-finish] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• CHO platform (CHO Platform): 2–10 g/L titers, reproducible cell line across molecules.
• Single-use bioprocess (Single-Use Bioprocessing): disposable bags/bioreactors for flexibility.
• High-throughput analytics (High-Throughput Analytics): PAT, mass spectrometry, charge profiling.

02US#

The US is the largest biologics market and leads on ATMP M&A and VC.

MAb & ADC leadership, M&A consolidation, FDA#

• AbbVie / Amgen: Humira (peak >$20B/year) and Enbrel; bispecifics.
• Pfizer → Seagen ($43B): consolidating ADC leadership.
• FDA: expedited pathways (Breakthrough, RMAT) for CAR-T and gene therapy.

03CN#

China is rapidly scaling biomanufacturing capacity and a biosimilar portfolio.

WuXi & biosimilar scale, NMPA pathway, capacity build-out#

• WuXi Biologics: the largest biologics CRDMO platform.
• Biosimilars: mass production of domestic mAb biosimilars.
• NMPA: accelerated approval for strategically important molecules.

04EU#

The EU is home to the largest biopharma giants and bioproduction-sovereignty programs.

Roche/Novartis/Sanofi, France Bioproduction 2030, EMA ATMP#

• Roche/Novartis/Sanofi: Herceptin, Kymriah, Dupixent — mAb/CAR-T/antibody flagships.
• France “Bioproduction 2030”: mAb production localisation, flexible iFab mini-plants.
• EMA ATMP: strict regulation of CAR-T and gene therapy.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack rests on the cell line, the bioreactor and deep purification.

1. CHO platform (CHO Cell-Line Platform):
   • fed-batch at 2–10 g/L titer; reproducible genetics across molecules.
   • case: Roche/Genentech — the benchmark large-scale mAb platform.
2. Single-use bioprocess (Single-Use Bioprocessing):
   • disposable bioreactors and bags cut capex and cross-contamination.
3. ADC conjugation (ADC Conjugation):
   • linker-payload chemistry for targeted cytotoxic delivery to tumours (Enhertu).

07Value chains and production pipelines#

Industrial pipeline of mAb production (GMP / ICH Q5A)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell line (CHO)        │ ───> │ 2. Upstream bioreactor    │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chromatography (Protein│ <─── │ 3. Harvest & clarification│
│    A + IEX) + viral safety│      │                           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. UF/DF & formulation    │ ───> │ 6. Fill-finish & QC       │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cell line

A stable CHO line with the target transgene is cloned and banked (MCB/WCB).

Stage 2: Upstream bioreactor

Fed-batch or perfusion in bioreactors reaches 2–10 g/L titer under PAT control.

Stage 3: Harvest & clarification

Centrifugation and depth filtration remove cells, yielding clarified liquor.

Stage 4: Chromatography & viral safety

Protein A → ion-exchange chromatography; viral inactivation and filtration (ICH Q5A).

Stage 5: UF/DF & formulation

Ultrafiltration/diafiltration concentrates the mAb and transfers it into formulation.

Stage 6: Fill-finish & QC

Sterile filling, lyophilisation (as needed), serialisation and batch release.